## 25<sup>th</sup> Nano Congress for Future Advancements

12<sup>th</sup> Edition of International Conference on

## Nanopharmaceutics and Advanced Drug Delivery

August 16-18, 2018 | Dublin, Ireland

# Optimizing transfection of primary human umbilical vein endothelial cells using facial amphipathic deoxycholic acid conjugated polyethyleneimine

Fatemeh Radmanesh<sup>1,2</sup>, Hamid Sadeghi Abandansari<sup>1</sup>, Sara Rajabi<sup>1</sup>, Mahdi Karimi<sup>3</sup>, Bahram Kazemi Demneh<sup>2</sup> and Hossein Baharvand<sup>1</sup> <sup>1</sup>Royan Institute for Stem Cell Biology and Technology - ACECR, Iran <sup>2</sup>Shahid Beheshti University of Medical Sciences, Iran <sup>3</sup>Iran University of Medical Sciences, Iran

**Introduction:** Currently, RNA interference (RNAi) based gene therapy has been investigated for treating various disease conditions. However, successful application of RNAi including siRNA or miRNA has been limited by several factors *in vitro* and *in vivo*. To overcome these challenges, various non-viral carriers have been developing for efficient RNAi-mediated gene silencing. However, it is necessary to improve the efficacy of these non-viral strategies to achieve desired therapeutic effect. In this study, we carried out synthesis, characterization, and optimization of a polymeric conjugate based on low molecular weight polyethylenimine which was modified by high membrane permeable deoxycholic acid conjugated polyethylenimine (DA PEI) for efficient delivery of RNAi-based therapeutics into primary human umbilical vein endothelial cells (HUVECs).

**Methodology:** Herein, DA-PEI conjugate was synthesized based on DCC/NHS chemistry at various DA to PEI molar ratios of 2 to 4 and used for delivery of a fluorescent labeled siRNA into HUVECs. Conjugates were characterized for chemical structure, size, and cell cytotoxicity. The effect of various parameters including DA/PEI molar ratio, polymer/siRNA weight ratio, and different buffer solutions was investigated on transfection efficacy of conjugates.

**Results:** DA was conjugated to the terminal amine groups of the PEI 1.8 via amide bonds. The polyplexes had smaller sizes (about 130~150 nm) than the parent PEI 1.8 at different weight ratios. MTS assay revealed that the conjugates were non-toxic at polymer concentrations used in transfection experiments. The higher intracellular uptake and transfection efficiency were achieved by the conjugates synthesized in DA/PEI molar ratio of 3 or 4, polymer/siRNA weight ratio of 5 when they were prepared in salty buffers.

**Conclusions:** These results suggest that the DA-PEI 1.8 conjugate can be applied as a promising candidate to enhance delivery of RNAi therapeutics into primary endothelial cells under the optimized transfection conditions.

### **Recent Publications**

- 1. Sepantafar M et al. (2017) Engineered hydrogels in cancer therapy and diagnosis. Trends in Biotechnology. 35(11):1074-1087.
- 2. Karimi M et al. (2016) Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chemical Society Reviews. 45(5):1457-1501.
- 3. Karimi M et al. (2016) pH-sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 8(5):696-716.
- 4. Karimi M et al. (2013) The novel albumin chitosan core-shell nanoparticles for gene delivery: preparation, optimization and cell uptake investigation. Journal of Nanoparticle Research. 15(4):1651.
- 5. Karimi M et al. (2013) Evaluation of chitosan-tripolyphosphate nanoparticles as a p-shRNA delivery vector: formulation, optimization and cellular uptake study. Journal of Nanopharmaceutics and Drug Delivery. 1(3):266-278.

### Biography

Fatemeh Radmanesh pursued BSc Biotechnology and MSc Microbial Biotechnology from University of Isfahan, Iran. She is currently a PhD student of Medical Biotechnology at Shahid Beheshti University of Medical Sciences. She is a Member of Royan Cardiovascular and Cell Engineering Group. She is interested in nanoparticulate delivery strategies, especially for RNAi-based therapeutics delivery. She joined Royan Institute in 2015 and pursued PhD thesis on using polymeric nanoparticles to deliver RNAi therapeutics.

rad.biotech89@gmail.com